The pan-deacetylase inhibitor panobinostat suppresses the expression of oncogenic miRNAs in hepatocellular carcinoma cell lines

Molecular Carcinogenesis

Volumn 54, Issue 8, 2015, Pages 585-597

  Henrici, Alexander ^a   Montalbano, Roberta ^a   Neureiter, Daniel ^b   Krause, Michael ^a   Stiewe, Thorsten ^a   Slater, Emily Prentice ^a   Quint, Karl ^a   Ocker, Matthias ^a   Di Fazio, Pietro ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

Deacetylase inhibitors; Epigenetic; Human miRNAs; Liver cancer; Protein expression modulation

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; BECLIN 1; MICRORNA; MICRORNA 19A; MICRORNA 19B1; MICRORNA 30A 5P; OLIGONUCLEOTIDE; P21 ACTIVATED KINASE 6; PANOBINOSTAT; PROTEIN P53; UNCLASSIFIED DRUG; APAF1 PROTEIN, HUMAN; APOPTOSIS REGULATORY PROTEIN; BECN1 PROTEIN, HUMAN; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; INDOLE DERIVATIVE; MEMBRANE PROTEIN; MIRN19 MICRORNA, HUMAN; MIRN30 MICRORNA, HUMAN; P21 ACTIVATED KINASE; PAK6 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOSOLIC FRACTION; GENE EXPRESSION REGULATION; HEPATOCELLULAR CARCINOMA CELL LINE; HEPG2 CELL LINE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOLECULAR MIMICRY; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; DRUG EFFECTS; GENETICS; LIVER TUMOR; METABOLISM; TUMOR CELL LINE;

APOPTOSIS REGULATORY PROTEINS; APOPTOTIC PROTEASE-ACTIVATING FACTOR 1; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INDOLES; LIVER NEOPLASMS; MEMBRANE PROTEINS; MICRORNAS; P21-ACTIVATED KINASES;

EID: 84937022947     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22122     Document Type: Article

References (50)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 1907-1917.
3. Ocker M, Schneider-Stock R. Histone deacetylase inhibitors: Signalling towards p21cip1/waf1. Int J Biochem Cell Biol 2007; 39:1367-1374.
4. Ocker M. Deacetylase inhibitors-Focus on non-histone targets and effects. World J Biol Chem 2010; 1:55-61.
5. Di Fazio P, Schneider-Stock R, Neureiter D, et al. The pan-deacetylase inhibitor panobinostat inhibits growth of hepatocellular carcinoma models by alternative pathways of apoptosis. Cell Oncol 2010; 32:285-300.
6. Montalbano R, Waldegger P, Quint K, et al. Endoplasmic reticulum stress plays a pivotal role in cell death mediated by the pan-deacetylase inhibitor panobinostat in human hepatocellular cancer cells. Transl Oncol 2013; 6:143-157.
7. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: Molecular mechanisms of action. Oncogene 2007; 26:5541-5552.
8. Scott GK, Mattie MD, Berger CE, Benz SC, Benz CC. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res 2006; 66:1277-1281.
9. Shin S, Lee EM, Cha HJ, et al. MicroRNAs that respond to histone deacetylase inhibitor SAHA and p53 in HCT116 human colon carcinoma cells. Int J Oncol 2009; 35:1343-1352.
10. Di Fazio P, Montalbano R, Neureiter D, et al. Downregulation of HMGA2 by the pan-deacetylase inhibitor panobinostat is dependent on hsa-let-7b expression in liver cancer cell lines. Exp Cell Res 2012; 318:1832-1843.
11. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75:843-854.
12. Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004; 101:2999-3004.
13. Garzon R, Calin GA, Croce CM. MicroRNAs in Cancer. Annu Rev Med 2009; 60:167-179.
14. Ruan K, Fang X, Ouyang G. MicroRNAs: Novel regulators in the hallmarks of human cancer. Cancer Lett 2009; 285:116-126.
15. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144:646-674.
16. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007; 302:1-12.
17. Olive V, Jiang I. He L. mir-17-92, a cluster of miRNAs in the midst of the cancer network. Int J Biochem Cell Biol 2010; 42:1348-1354.
18. Park CW, Zeng Y, Zhang X, Subramanian S, Steer CJ. Mature microRNAs identified in highly purified nuclei from HCT116 colon cancer cells. RNA Biol 2010; 7:606-614.
19. Gerets HH, Tilmant K, Gerin B, et al. Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol 2012; 28:69-87.
20. Chen H, Cui L, Jiang XY, et al. Evaluation of the cytotoxicity of cigarette smoke condensate by a cellular impedance biosensor. Food Chem Toxicol 2012; 50:612-618.
21. van Rooij E. The art of microRNA research. Circ Res 2011; 108:219-234.
22. Chen BZ, Yu SL, Singh S, et al. Identification of microRNAs expressed highly in pancreatic islet-like cell clusters differentiated from human embryonic stem cells. Cell Biol Int 2011; 35:29-37.
23. Ocker M. Editorial: novel aspects of apoptosis modulating drugs. Curr Pharm Biotechnol 2011; 13:2182-2183.
24. Di Fazio P, Ocker M, Montalbano R. New drugs, old fashioned ways: Er stress induced cell death. Curr Pharm Biotechnol 2011; 13:2228-2234.
25. Rao R, Balusu R, Fiskus W, et al. Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells. Mol Cancer Ther 2012; 11:973-983.
26. Sampath D, Liu C, Vasan K, et al. Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia. Blood 2012; 119:1162-1172.
27. Liu Q, Lv GD, Qin X, et al. Role of microRNA let-7 and effect to HMGA2 in esophageal squamous cell carcinoma. Mol Biol Rep 2011; 39:1239-1246.
28. Sampson VB, Rong NH, Han J, et al. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res 2007; 67:9762-9770.
29. Zhang BG, Li JF, Yu BQ, Zhu ZG, Liu BY, Yan M. microRNA-21 promotes tumor proliferation and invasion in gastric cancer by targeting PTEN. Oncol Reports 2012; 27:1019-1026.
30. Liu ZL, Wang H, Liu J, Wang ZX. MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN. Mol Cell Biochem 2012; 372:35-45.
31. Ota A, Tagawa H, Karnan S, et al. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res 2004; 64:3087-3095.
32. He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature 2005; 435:828-833.
33. Hayashita Y, Osada H, Tatematsu Y, et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005; 65:9628-9632.
34. Li Y, Tan W, Neo TW, et al. Role of the miR-106b-25 microRNA cluster in hepatocellular carcinoma. Cancer Sci 2009; 100:1234-1242.
35. Connolly E, Melegari M, Landgraf P, et al. Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirusassociated hepatocellular carcinoma contributes to the malignant phenotype. Am J Pathol 2008; 173:856-864.
36. Xi Y, Formentini A, Chien M, et al. Prognostic values of microRNAs in colorectal cancer. Biomark Insights 2006; 2:113-121.
37. Kim Y, Kim VN. MicroRNA factory: RISC assembly from precursor microRNAs. Mol Cell 2012; 46:384-386.
38. Trabucchi M, Briata P, Garcia-Mayoral M, et al. The RNA-binding protein KSRP promotes the biogenesis of a subset of microRNAs. Nature 2009; 459:1010-1014.
39. Piskounova E, Viswanathan SR, Janas M, et al. Determinants of microRNA processing inhibition by the developmentally regulated RNA-binding protein Lin28. J Biol Chem 2008; 283:21310-21314.
40. Landgraf P, Rusu M, Sheridan R, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 2007; 129:1401-1414.
41. Smith MI, Deshmukh M. Endoplasmic reticulum stress-induced apoptosis requires bax for commitment and Apaf-1 for execution in primary neurons. Cell Death Differ 2007; 14:1011-1019.
42. Shao Y, Gao Z, Marks PA, Jiang X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci U S A 2004; 101:18030-18035.
43. Mehrpour M, Esclatine A, Beau I, Codogno P. Autophagy in health and disease. 1. Regulation and significance of autophagy: An overview. Am J Physiol Cell Physiol 2010; 298:C776-C785.
44. Lee JY, Koga H, Kawaguchi Y, et al. HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy. EMBO J 2010; 969-980.
45. Qu X, Yu J, Bhagat G, et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest 2003; 112:1809-1820.
46. Kisen GO, Tessitore L, Costelli P, et al. Reduced autophagic activity in primary rat hepatocellular carcinoma and ascites hepatoma cells. Carcinogenesis 1993; 14:2501-2505.
47. Fung W-y. The characterization of PAK 6 in liver cancer. Uiversity of Hong Kong; 2009.
48. Wells CM, Jones GE. The emerging importance of group II PAKs. Biochem J 2010; 425:465-473.
49. Zhang M, Siedow M, Saia G, Chakravarti A. Inhibition of p21-activated kinase 6 (PAK6) increases radiosensitivity of prostate cancer cells. Prostate 2010; 70:807-816.
50. Gahr S, Wissniowski T, Zopf S, Strobel D, Pustowka A, Ocker M. Combination of the deacetylase inhibitor panobinostat and the multi-kinase inhibitor sorafenib for the treatment of metastatic hepatocellular carcinoma - review of the underlying molecular mechanisms and first case report. J Cancer 2012; 3:158-165.